THC trades 50.4% below Wall Street's consensus target of $259.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes THC achieves its forward estimates and maintains a stable P/E multiple of 9.6x. This scenario reflects the blended consensus of 32 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 21, 2026, Tenet Healthcare Corporation (THC) has a Wall Street consensus price target of $259.50, based on estimates from 32 covering analysts. With the stock currently trading at $172.57, this represents a potential upside of +50.4%. The company has a market capitalization of $15.12B.
Analyst price targets range from a low of $210.00 to a high of $288.00, representing a 30% spread in expectations. The median target of $262.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 26 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, THC trades at a trailing P/E of 11.1x and forward P/E of 9.6x. The forward PEG ratio of 0.29 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow -8.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $192.22, with bear and bull scenarios of $121.10 and $253.27 respectively. Model confidence stands at 57/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
HCAHCA Healthcare, Inc. | $83.9B | $375.17 | $504.73 | +34.5% | Buy | 12.4x | 46 |
CYHCommunity Health Systems, Inc. | $426M | $3.02 | $2.93 | -3.0% | Hold | — | 37 |
UHSUniversal Health Services, Inc. | $8.8B | $141.17 | $216.00 | +53.0% | Hold | 6.0x | 43 |
ENSGThe Ensign Group, Inc. | $9.0B | $153.65 | $222.33 | +44.7% | Buy | 20.3x | 13 |
SEMSelect Medical Holdings Corporation | $2.1B | $16.54 | $17.75 | +7.3% | Hold | 13.6x | 14 |
ACHCAcadia Healthcare Company, Inc. | $2.3B | $24.87 | $28.33 | +13.9% | Buy | 16.5x | 25 |
USPHU.S. Physical Therapy, Inc. | $964M | $63.32 | $96.00 | +51.6% | Buy | 21.9x | 13 |
NHCNational HealthCare Corporation | $3.1B | $201.53 | — | — | — | 25.3x | — |
SGRYSurgery Partners, Inc. | $1.9B | $14.55 | $19.33 | +32.9% | Buy | 33.9x | 22 |
UNHUnitedHealth Group Incorporated | $363.9B | $400.96 | $425.81 | +6.2% | Buy | 21.8x | 52 |
Quick answers to the most common questions about buying THC stock.
The consensus Wall Street price target for THC is $259.5, representing 50.4% upside from the current price of $172.57. With 32 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
THC has a consensus rating of "Buy" based on 32 Wall Street analysts. The rating breakdown is predominantly bullish, with 26 Buy/Strong Buy ratings. The consensus 12-month price target of $259.5 implies 50.4% upside from current levels.
With a forward P/E of 9.6493x, THC trades at a relatively low valuation. The consensus target of $259.5 implies 50.4% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $288 for THC, while the most conservative target is $210. The consensus of $259.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $253 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
THC is heavily covered by Wall Street, with 32 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 26 have Buy ratings, 6 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month THC stock forecast based on 32 Wall Street analysts shows a consensus price target of $259.5, with estimates ranging from $210 (bear case) to $288 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $192, with bear/bull scenarios of $121/$253.
Our quantitative valuation model calculates THC's fair value at $192 (base case), with a bear case of $121 and bull case of $253. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 57/100.
THC trades at a forward P/E ratio of 9.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 11.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on THC, with a "Buy" consensus rating and $259.5 price target (50.4% upside). 26 of 32 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
THC analyst price targets range from $210 to $288, a 30% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $259.5 consensus represents the middle ground. Our model's $121-$253 range provides an independent fundamental perspective.
Deep dive into THC consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.